You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
复星医药(600196.SH):聘任Aimin Hui为公司执行总裁
格隆汇 03-05 18:18

格隆汇 3 月 5日丨复星医药(600196.SH)公布,公司第届董事会三十次会议(临时会议)召开,审议通过关于聘任高级管理人员的议案。

经首席执行官提名,同意聘任Aimin Hui公司执行总裁,聘任李胜利、冯蓉丽公司高级副总裁,聘任Lihui Zou公司副总裁。上述人员任期均自202135日起至本届董事会任期届满之日止。

Aimin Hui196211月出生,于201711月加入集团201711月至20213月任公司高级副总裁20213月起任公司执行总裁。加入集团前,Aimin Hui19849月至19903月任河北医科大学第四医院医师,19904月至19913月任日本国立癌中心医院研修生,19914月至19949月任日本信州大学医学院博士研究生,19941019979月任日本国立癌中心/日本科学技术厅特别研究员,199710月至200010月任东京大学医学院文部教官助理教授、讲师,200010月至200612月任美国国立癌研究所访问科学家、研究员,20071月至200812月任GE医疗集团医学总监,20091月至20104月任Cephalon, Inc.医学总监,20104月至201511月历任武田药品工业株式会社临床肿瘤学总监、高级总监,201511月至201710月任赛诺菲全球临床研发副总裁。

Aimin Hui现任香港联交所上市公司上海复宏汉霖生物技术股份有限公司(股份代号:02696)非执行董事。Aimin Hui19848月获河北医科大学医学学士学位,于19949月获日本信州大学医学院博士学位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account